Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 12/20 | 0.43 |
| ▸ | ADRB1 | P08588 | 11/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 8/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.43 |
| ▸ | DRD2 | P14416 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | DRD3 | P35462 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3263408 | 1.00 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL3065104 | 1.00 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL13090601 | 1.00 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL14740574 | 1.00 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL967513 | 0.94 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL2056235 | 0.94 | ADRB2 (0.43) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL14739592 | 0.93 | ADRB2 (0.44) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL3070170 | 0.93 | ADRB2 (0.44) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL12388210 | 0.92 | ADRB2 (0.39) | ADRB2ADRB1ADRB3CYP2D6ADRA1A | |
| SCHEMBL12388208 | 0.92 | ADRB2 (0.39) | ADRB2ADRB1ADRB3CYP2D6ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | JOHNSON MICHAEL ROSS (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | JOHNSON MICHAEL ROSS (US) | 2013-03-07 | — | — | US | disclosed |
| US-8324218-B2 | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity | PARION SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324218-B2 | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity | PARION SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-8324218-B2 | Aliphatic pyrazinoylguanidine sodium channel blockers with beta agonist activity | PARION SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | PARION SCIENCES, INC. (US) | 2010-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267746-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | ADRB1, ADRB2, ADRA2B | ADRB2 2/4885ADRB1 1/4885ADRB3 5/4885 |
| US-20130060034-A1 | ALIPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS WITH BETA AGONIST ACTIVITY | SCNN1G, SCNN1B, TRPV1 | ADRB2 21/4885ADRB1 20/4885ADRB3 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.